IS2442B - Hindrar á nituroxíðþétta - Google Patents

Hindrar á nituroxíðþétta

Info

Publication number
IS2442B
IS2442B IS5723A IS5723A IS2442B IS 2442 B IS2442 B IS 2442B IS 5723 A IS5723 A IS 5723A IS 5723 A IS5723 A IS 5723A IS 2442 B IS2442 B IS 2442B
Authority
IS
Iceland
Prior art keywords
inhibitors
nitric oxide
oxide condensate
condensate
nitric
Prior art date
Application number
IS5723A
Other languages
English (en)
Other versions
IS5723A (is
Inventor
John Beswick Paul
Kleanthous Savvas
John Young Robert
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS5723A publication Critical patent/IS5723A/is
Publication of IS2442B publication Critical patent/IS2442B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IS5723A 1998-05-30 2000-11-21 Hindrar á nituroxíðþétta IS2442B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9811599.1A GB9811599D0 (en) 1998-05-30 1998-05-30 Nitric oxide synthase inhibitors
PCT/EP1999/003583 WO1999062875A1 (en) 1998-05-30 1999-05-27 Nitric oxide synthase inhibitors

Publications (2)

Publication Number Publication Date
IS5723A IS5723A (is) 2000-11-21
IS2442B true IS2442B (is) 2008-11-15

Family

ID=10832929

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5723A IS2442B (is) 1998-05-30 2000-11-21 Hindrar á nituroxíðþétta

Country Status (30)

Country Link
US (2) US6355689B1 (is)
EP (1) EP1084104B1 (is)
JP (1) JP3839256B2 (is)
KR (1) KR20010043920A (is)
CN (1) CN1218940C (is)
AP (1) AP1382A (is)
AT (1) ATE245142T1 (is)
AU (1) AU757042B2 (is)
BR (1) BR9910849A (is)
CA (1) CA2333322C (is)
CZ (1) CZ297473B6 (is)
DE (1) DE69909625T2 (is)
DK (1) DK1084104T3 (is)
EA (1) EA003026B1 (is)
EE (1) EE04149B1 (is)
ES (1) ES2203147T3 (is)
GB (1) GB9811599D0 (is)
HU (1) HUP0102472A3 (is)
ID (1) ID26790A (is)
IL (1) IL139697A (is)
IS (1) IS2442B (is)
NO (1) NO20006044L (is)
NZ (1) NZ508222A (is)
PL (1) PL194784B1 (is)
PT (1) PT1084104E (is)
RS (1) RS49984B (is)
SK (1) SK18052000A3 (is)
TR (1) TR200003539T2 (is)
WO (1) WO1999062875A1 (is)
ZA (1) ZA200006847B (is)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1265859T3 (da) * 2000-03-24 2006-05-01 Pharmacia Corp Amidinoforbindelser der er nyttige som nitrogenoxidsyntaseinhibitorer
US7012098B2 (en) 2001-03-23 2006-03-14 Pharmacia Corporation Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
JPWO2003022309A1 (ja) * 2001-09-10 2004-12-24 小野薬品工業株式会社 アレルギー疾患治療剤
US20030109522A1 (en) * 2001-09-24 2003-06-12 Manning Pamela T. Ophthalmologic treatment methods using selective iNOS inhibitors
CN1652843A (zh) * 2002-05-16 2005-08-10 法玛西雅公司 使用选择性iNOS抑制剂治疗呼吸系统疾病和病症
US20040087653A1 (en) * 2002-05-16 2004-05-06 Manning Pamela T. Methods for the treatment of respiratory diseases and conditions with a selective iNOS inhibitor and a PDE inhibitor and compositions therefor
MXPA05001255A (es) * 2002-08-02 2005-06-08 Pharmacia Corp Metodos para el tratamiento y prevencion de condiciones gastrointestinales.
US20060247216A1 (en) * 2002-10-25 2006-11-02 Haj-Yehia Abdullah I Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
EP1578413A2 (en) * 2002-11-29 2005-09-28 Yissum Research Development Company of The Hebrew University of Jerusalem Ace-inhibitors having antioxidant and no-donor activity
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
GB0316212D0 (en) * 2003-07-10 2003-08-13 Glaxo Group Ltd Novel compounds
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
WO2005025620A2 (en) * 2003-08-13 2005-03-24 Pharmacia Corporation Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
EP1841780B1 (en) 2005-01-10 2011-07-27 Glaxo Group Limited Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
PE20061193A1 (es) 2005-03-25 2006-12-02 Glaxo Group Ltd DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
MY145343A (en) 2005-03-25 2012-01-31 Glaxo Group Ltd Novel compounds
JPWO2007000884A1 (ja) * 2005-06-29 2009-01-22 国立大学法人金沢大学 骨・関節疾患の予防・治療剤およびそのスクリーニング方法
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
TW200730498A (en) 2005-12-20 2007-08-16 Glaxo Group Ltd Compounds
KR20090003349A (ko) 2006-04-20 2009-01-09 글락소 그룹 리미티드 화합물
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
CA2659539A1 (en) 2006-08-01 2008-02-07 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
CA2669138A1 (en) * 2006-11-09 2008-12-04 University Of Maryland, Baltimore Use of 5,6-dimethylxanthenone-4-acetic acid as an antimicrobial agent
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
BRPI0912267A2 (pt) 2008-05-23 2015-10-13 Amira Pharmaceuticals Inc sal farmaceuticamente aceitável, composição farmacêutica, artigo de fabricação, métodos para tratar asma, rinite alérgica, doença, lesões gástricas e dor, métodos para prevenir broncoconstrição e rinite alérgica, uso de um sal farmaceuticamente aceitável, e, processo para a preparação de um sal farmaceuticamente aceitável.
ES2566339T3 (es) 2008-06-05 2016-04-12 Glaxo Group Limited Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas
JP5502077B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド 新規な化合物
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
JP2012520257A (ja) 2009-03-10 2012-09-06 グラクソ グループ リミテッド Ｉｋｋ２阻害剤としてのインドール誘導体
EP2408769A1 (en) 2009-03-17 2012-01-25 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
WO2010107958A1 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EA201171144A1 (ru) 2009-03-19 2012-04-30 Мерк Шарп Энд Домэ Корп. ОПОСРЕДОВАННОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНА ГОМОЛОГА 1 BTB И CNC, ОСНОВНОГО ФАКТОРА ТРАНСКРИПЦИИ С ЛЕЙЦИНОВОЙ МОЛНИЕЙ 1 (Bach1) С ИСПОЛЬЗОВАНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
EP2408916A2 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012520685A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＧＡＴＡ結合タンパク質３（ＧＡＴＡ３）遺伝子発現のＲＮＡ干渉媒介性阻害
WO2010111468A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
KR20110138223A (ko) 2009-03-27 2011-12-26 머크 샤프 앤드 돔 코포레이션 짧은 간섭 핵산 (ｓｉＮＡ)을 사용한 세포간 부착 분자 1 (ＩＣＡＭ-1) 유전자 발현의 ＲＮＡ 간섭 매개 억제
US20120022142A1 (en) 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
JP2012521760A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたアポトーシスシグナル調節キナーゼ１（ＡＳＫ１）遺伝子発現のＲＮＡ干渉媒介性阻害
US20120022143A1 (en) 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA)
US20100273744A1 (en) 2009-04-24 2010-10-28 Paul Martin Gore Compounds
EP2421834A1 (en) 2009-04-24 2012-02-29 Glaxo Group Limited Pyrazole and triazole carboxamides as crac channel inhibitors
CN102459253B (zh) 2009-04-30 2015-03-25 葛兰素集团有限公司 作为pi3-激酶抑制剂的*唑取代的吲唑化合物
US20120238559A1 (en) 2009-12-03 2012-09-20 Glaxo Group Limited Novel compounds
WO2011067366A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
EP2507223A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
US20120272951A1 (en) 2009-12-16 2012-11-01 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
TWI375671B (en) * 2010-03-01 2012-11-01 Univ China Medical Pharmaceutical compositions containing brazilin for inhibiting expression of cytokines of t helper cell type ii and/or inhibiting expression of chemokines and uses of the same
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
JP5965402B2 (ja) 2010-09-08 2016-08-03 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｎ−［５−［４−（５−｛［（２ｒ，６ｓ）−２，６−ジメチル−４−モルホリニル］メチル｝−１，３−オキサゾール−２−イル）−１ｈ−インダゾール−６−イル］−２−（メチルオキシ）−３−ピリジニル］メタンスルホンアミドの多形体および塩
WO2012032065A1 (en) 2010-09-08 2012-03-15 Glaxo Group Limited Indazole derivatives for use in the treatment of influenza virus infection
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
EP2630127A1 (en) 2010-10-21 2013-08-28 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
EP2630126B1 (en) 2010-10-21 2015-01-07 Glaxo Group Limited Pyrazole compounds acting against allergic, immune and inflammatory conditions
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
US20140005188A1 (en) 2011-03-11 2014-01-02 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
KR20160060100A (ko) 2013-09-22 2016-05-27 칼리토르 사이언시즈, 엘엘씨 치환된 아미노피리미딘 화합물 및 이용 방법
WO2015148868A1 (en) 2014-03-28 2015-10-01 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
TW201625247A (zh) 2014-05-12 2016-07-16 葛蘭素史密斯克藍智慧財產權有限公司 用於治療傳染性疾病之醫藥組合物
US9938257B2 (en) 2015-09-11 2018-04-10 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
US10683297B2 (en) 2017-11-19 2020-06-16 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
CA3083040A1 (en) 2018-01-20 2019-07-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
EP4125919A1 (en) 2020-03-26 2023-02-08 GlaxoSmithKline Intellectual Property Development Limited Cathepsin inhibitors for preventing or treating viral infections

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2049582A (en) 1931-11-04 1936-08-04 Rohm & Haas Amidines
US4085217A (en) 1964-01-29 1978-04-18 L'oreal Process and cosmetic compositions for the treatment of skin and scalp
US4085218A (en) 1975-10-30 1978-04-18 Sandoz Ltd. Elevating mood in geriatric patients
US4512979A (en) 1981-03-23 1985-04-23 Merck & Co., Inc. Dipeptides containing thialysine and related amino acids as antihypertensives
EP0068173B1 (en) 1981-06-05 1984-09-26 Merck & Co. Inc. Perhydro-1,4-thiazepin-5-one and perhydro-1,4-thiazocin-5-one derivatives, process for preparing and pharmceutical composition containing the same
US4594341A (en) 1982-04-06 1986-06-10 Merck & Co., Inc. Perhydro-1,4-thiazepin-5-one and perhydro-1,4-thiazocin-5-one derivatives as antihypertensives
FI832053L (fi) 1982-06-10 1983-12-11 Syntex Inc Nonapeptid- och dekapeptidanaloger av lhrh anvaendbara som lhrh-antagonister samt deras framstaellningsfoerfarande
DE3514450A1 (de) 1985-04-22 1986-10-23 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von imidaten sowie neue arylsubstituierte imidate
US5028627A (en) 1989-09-13 1991-07-02 Cornell Research Foundation, Inc. Method of using arginine derivatives to inhibit systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor
GB8929076D0 (en) 1989-12-22 1990-02-28 Scras Treatment of shock by blocking agents of edrf effect or formation
AU636713B2 (en) 1990-02-26 1993-05-06 Merrell Dow Pharmaceuticals Inc. Inhibitors of nitric oxide biosynthesis
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
DE4310202A1 (de) 1992-03-30 1993-10-07 Ciba Geigy µ-Ketoimidoester als Stabilisatoren für chlorhaltige Polymerisate
US5281627A (en) 1992-05-28 1994-01-25 Cornell Research Foundation, Inc. Substituted arginines and substituted homoarginines and use thereof
US5585402A (en) 1992-12-23 1996-12-17 Glaxo Wellcome Inc. Nitric oxide synthase inhibitors
US5364881A (en) 1993-11-15 1994-11-15 The Medical College Of Wisconsin Research Foundation, Inc. S-alkyl-isothioureido-amino acids and use thereof
SI0765308T1 (sl) 1994-06-15 2000-08-31 The Wellcome Foundation Limited Encimski inhibitorji
FR2727111B1 (fr) 1994-11-21 1997-01-17 Hoechst Lab Nouveaux analogues soufres d'aminoacides, leur procede de preparation et leurs applications comme medicaments
MY117948A (en) * 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.

Also Published As

Publication number Publication date
DK1084104T3 (da) 2003-10-27
GB9811599D0 (en) 1998-07-29
CN1218940C (zh) 2005-09-14
ID26790A (id) 2001-02-08
DE69909625T2 (de) 2004-06-24
JP3839256B2 (ja) 2006-11-01
PL344368A1 (en) 2001-11-05
RS49984B (sr) 2008-09-29
EE04149B1 (et) 2003-10-15
AP1382A (en) 2005-04-01
EA003026B1 (ru) 2002-12-26
IL139697A (en) 2005-12-18
AU757042B2 (en) 2003-01-30
CA2333322C (en) 2008-01-22
EA200001122A1 (ru) 2001-06-25
EP1084104B1 (en) 2003-07-16
JP2002516901A (ja) 2002-06-11
ATE245142T1 (de) 2003-08-15
ES2203147T3 (es) 2004-04-01
CZ297473B6 (cs) 2006-12-13
PT1084104E (pt) 2003-11-28
CA2333322A1 (en) 1999-12-09
HUP0102472A2 (hu) 2002-03-28
IL139697A0 (en) 2002-02-10
SK18052000A3 (sk) 2001-06-11
HUP0102472A3 (en) 2002-12-28
KR20010043920A (ko) 2001-05-25
BR9910849A (pt) 2001-02-20
WO1999062875A1 (en) 1999-12-09
YU74600A (sh) 2002-12-10
EP1084104A1 (en) 2001-03-21
NO20006044D0 (no) 2000-11-29
ZA200006847B (en) 2001-11-22
IS5723A (is) 2000-11-21
AP2000001998A0 (en) 2000-12-31
NO20006044L (no) 2001-01-29
CN1303367A (zh) 2001-07-11
AU4367199A (en) 1999-12-20
TR200003539T2 (tr) 2001-06-21
NZ508222A (en) 2003-02-28
CZ20004450A3 (en) 2001-05-16
HK1034241A1 (en) 2001-10-19
US6355689B1 (en) 2002-03-12
US6495606B1 (en) 2002-12-17
PL194784B1 (pl) 2007-07-31
EE200000716A (et) 2002-04-15
DE69909625D1 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
IS2442B (is) Hindrar á nituroxíðþétta
EE04013B1 (et) Lämmastikoksiidi süntaasi inhibiitorid
TR199900520A3 (tr) Bilesik ve kullanimi.
ID25977A (id) Popok sekali pakai
ID23076A (id) Popok sekali pakai
DE69941926D1 (de) Bioabbaubare karte
DK1070058T3 (da) (4-Arylsulfonylamino)-tetrahydropyran-4-carboxylsyrehydroxamider
NO990113D0 (no) Flerskrog-fart°y
DK1100769T3 (da) Aminomethylcarboxylsyrederivater
NO992198D0 (no) R°rledningspigg
ID23083A (id) Popok sekali pakai
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
NO20010085D0 (no) Angiogeneseinhibitorer
DE69903507D1 (de) Beizvorrichtung
DE69901764D1 (de) Beizvorrichtung
DE19983730T1 (de) Yttriumchromit-Chromoxid-Thermistoren
NO20010904L (no) Korrosjonsinhibitor
ATA8298A (de) Schreibgerät
TR199901535A3 (tr) Siklooksigenaz önleyicisi.
DK1317478T3 (da) Skelnen mellem GnRH-I og GnRH-II
IT1304341B1 (it) Trasformatore planare.
DE69930852D1 (de) Prenyltransferase-inhibitoren
NO20031636D0 (no) Korrosjonsinhibitor
DE19981560D2 (de) Heizkessel
NO990802L (no) Optimalisert spoledrift